Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Roots Analysis | PRODUCT CODE: 1064479

Cover Image

PUBLISHER: Roots Analysis | PRODUCT CODE: 1064479

Continuous Manufacturing (Small Molecules and Biologics) Market (2nd Edition): Distribution by Purpose of Manufacturing (In-House and Contract Services), Scale of Operation (Preclinical, Clinical and Commercial),

PUBLISHED:
PAGES: 376 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 5899
PDF (Site License)
USD 7999
PDF (Enterprise License)
USD 17999

Add to Cart

Title:
Continuous Manufacturing (Small Molecules and Biologics) Market (2nd Edition):
Distribution by Purpose of Manufacturing (In-House and Contract Services), Scale of Operation (Preclinical, Clinical and Commercial), Type of Drug Molecule (Biologic and Small Molecule), Type of Continuous Manufacturing Related Service Offered (Process Development, API Manufacturing, Intermediate Manufacturing, Drug Product Manufacturing, and Packaging and Fill / Finish), Type of Dosage Form Offered (Solid and Liquid), Installed Capacity and Geographical Regions (North America, Europe and Asia-Pacific), 2022-2035.

Example Insights:

Overview

Over time, advances in manufacturing technologies have prompted pharmaceutical companies to shift from the traditional multi-step, batch manufacturing processes to faster and relatively efficient continuous manufacturing. Continuous manufacturing, also known as continuous flow chemistry, is an advanced manufacturing technology, which drives operations in a continuous manner (24x7) in one facility, without hold times. The concept was first described in the 1700s, for the production of pig iron in blast furnaces. Since then, the technique has been adopted by various industries, including automotive, food and beverage, oil refining, chemicals, pulp and paper, electronics, metal smelting, steel making, and waste-water treatment industries. In recent years, continuous manufacturing has gained traction in the biopharmaceutical industry as well, having captured the attention of big pharma players, as well as leading contract manufacturing organizations (CMOs). Moreover, the ongoing COVID-19 pandemic has prompted the pharmaceutical industry to shift to continuous manufacturing to scale up processing. The continuous manufacturing technology offers several benefits, including reduction in manufacturing cost (by 15-30%), manpower (by 50-70%) and power consumption (by 40%), lesser product deviation (by 50%), smaller footprint (by 50-70%) and faster scale up. Specifically, for biologics, continuous manufacturing, through upstream perfusion, is already a well-established method. In fact, more than 20 biologics manufactured using this approach have been approved by the FDA. Moreover, continuous processing technology presents a versatile and beneficial manufacturing approach for oral solid dosage (OSD) forms and small molecules as well. In the last few years, many orally administrable drugs, including TRIKAFTA® (Vertex Pharmaceuticals, 2019), DAURISMO™ (Pfizer, 2018), SYMDEKO® (Vertex Pharmaceuticals, 2018), VERZENIO® (Eli Lilly, 2017), PREZISTA® (Johnson & Johnson, 2016) and ORKAMBI® (Vertex Pharmaceuticals, 2015) manufactured using the continuous technique, have been approved by the FDA.

Presently, several technology providers / equipment suppliers are engaged in offering the necessary technologies and equipment for continuous manufacturing; these include continuous flow reactors (plug flow reactors, continuous stirred tank reactors (CSTR) and microreactors), continuous granulators, continuous coaters, continuous mixers / blenders, continuous chromatography equipment, continuous dryers and process analytical technologies (PAT). Additionally, many companies have made heavy investments in order to install this technology and expand their facilities and capabilities. Innovators in this field have received significant support in the form of grants from various administering institutes and incentives from key regulatory agencies as well. It is also important to highlight that, despite the ongoing efforts, the adoption of this technology is fraught with some challenges, including cost of equipment, process development restrictions, manufacturing of a new facility and maintenance of the equipment. However, owing to the rising interest of investors and technological advancements, we are led to believe that the opportunity for technology developers and manufacturers / users engaged in this domain is likely to grow in the foreseen future.

Scope of the Report

The "Continuous Manufacturing (Small Molecules and Biologics) Market (2nd Edition), 2022 - 2035, Distribution by Purpose of Manufacturing (In-House and Contract Services), Scale of Operation (Preclinical, Clinical and Commercial), Type of Drug Molecule (Biologic and Small Molecule), Type of Continuous Manufacturing Related Service Offered (Process Development, API Manufacturing, Intermediate Manufacturing, Drug Product Manufacturing, and Packaging and Fill / Finish), Type of Dosage Form Offered (Solid and Liquid), Installed Capacity and Geographical Regions (North America, Europe and Asia-Pacific)" report features an extensive study of the current market landscape and future opportunities for companies with capabilities in continuous manufacturing (both innovator companies with in-house expertise and contract manufacturers). It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the overall landscape of companies with capabilities for continuous manufacturing, along with information on a number of relevant parameters, such as year of establishment, company size, purpose of manufacturing (in-house and contract services), scale of operation (preclinical, clinical and commercial), location of headquarters, location of manufacturing facilities, type of drug molecule (biologic and small molecule), type of continuous manufacturing related service(s) offered (process development, API manufacturing, intermediate manufacturing, drug product manufacturing, and packaging and fill / finish), type of dosage form (solid and liquid), and installed capacity and batch size (if available).
  • Elaborate profiles of some of the companies active in the pharmaceutical and biopharmaceutical continuous manufacturing market in North America, Europe and Asia-Pacific. Each profile features an overview of the company, along with information related to its service portfolio, continuous manufacturing capabilities and facilities, recent developments and an informed future outlook.
  • An analysis of the various partnerships related to continuous manufacturing, which have been established since 2013, based on several parameters, such as year of an agreement, the type of partnership (research agreements, facility development / establishment agreements, technology enhancement agreements, service alliances, process development agreements, manufacturing agreements and other relevant agreements), scale of operation (preclinical, clinical and commercial), type of drug molecule (biologic and small molecule), type of continuous manufacturing related service (API manufacturing, intermediate manufacturing and end product manufacturing) and type of dosage form (solid and liquid). It also highlights the regional distribution of the collaborations.
  • An analysis of the expansions undertaken by companies engaged in continuous manufacturing, based on several parameters, such as year of expansion and the type of expansion (facility / plant expansion, technology installation, technology enhancement and service expansion), geographical location of the facility, scale of operation (preclinical, clinical and commercial), type of drug molecule (biologic and small molecule), type of continuous manufacturing related service (API manufacturing, intermediate manufacturing and end product manufacturing) and type of dosage form (solid and liquid).
  • A detailed competitiveness analysis of companies having expertise in continuous manufacturing, based on various relevant parameters, such as years of experience (YoE- the current year), company size, scale of production (pre-clinical, clinical and commercial), type of services (process development, drug substance manufacturing, intermediate manufacturing, final dosage form, packaging and labelling) and geographical location.
  • An estimate of the global, continuous manufacturing capacity, based on the capacities of various industry stakeholders (as available on their respective company websites) . The study includes analysis of capacity, based on the type of drug molecule (biologic and small molecule), company size (small-sized, mid-sized and large), scale of operation (preclinical, clinical and commercial), location of headquarters (North America, Europe and Asia-Pacific) and location of manufacturing facilities (North America, Europe and Asia-Pacific).
  • A study of the various grants that have been awarded to research institutes engaged in projects related to continuous manufacturing, between 2016 and 2021, highlighting multiple parameters, such as year of award, type of grant, grant amount, focus area, support period, popular recipient organizations, type of recipient organization, funding institute center, funding mechanism and prominent program officers.
  • An in-depth analysis of the various patents that have been filed / granted related to continuous manufacturing till 2021, based on the parameters, such as patent type, publication year, geographical location, CPC symbol, emerging focus areas, type of applicant and leading industry / non-industry players (in terms of the size of intellectual property portfolio) . It also features a three-dimensional bubble analysis (based on patent citation count, publication year, extended geographical reach) , patent benchmarking and a detailed patent valuation analysis.
  • Initiatives taken by the leading pharmaceutical companies (in terms of revenues), covering both partnered as well as in-house projects.
  • An overview of the companies offering modular facilities / modular cleanrooms, including information on their geographical location (North America, Europe, Asia-Pacific and rest of the world), year of establishment, company size (small-sized, mid-sized or large) and type of industries served (pharmaceutical, biotechnology or others). It also provides details on the recent projects undertaken / executed by the companies providing modular facilities.
  • A case study of the companies offering technologies / equipment (continuous blenders and mixers, continuous granulators, continuous dryers, continuous compressors, continuous coaters, flow reactors, continuous filtration, distillation and centrifugation equipment, continuous chromatography, PAT technology and other technologies) that can potentially be used in a continuous manufacturing process, providing information on the geographical location of potential stakeholders and the type of technology / equipment provided.
  • A case study on the roadmap for the adoption of continuous manufacturing technique, discussing different strategies that can be followed by the company in order to adopt this technology or transition from batch manufacturing to continuous manufacturing.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as overall market of the currently approved drugs based on continuous manufacturing, cost of goods sold and direct manufacturing cost, we have provided an informed estimate of the likely evolution of the market in the mid to long term, for the time period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] purpose of manufacturing (in-house and contract services) [B] scale of operation (preclinical, clinical and commercial), [C] type of drug molecule (small molecule and biologic), [D] type of continuous manufacturing related service (API manufacturing and end product manufacturing), [E] type of dosage form (solid and liquid) and [F] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). To account for the uncertainties associated with the continuous manufacturing of pharmaceuticals and biopharmaceuticals and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in this study were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Andrea Adamo (Founder and Chief Executive Officer, Zaiput Flow Technologies)
  • Bayan Takizawa (Co-Founder and Chief Business Officer, CONTINUUS Pharmaceuticals)
  • Eric Fang (Chief Scientific Officer, Snapdragon Chemistry)
  • Himanshu Gadgil (Director and Chief Scientific Officer, Enzene Biosciences)
  • Nick Thomson (Senior Director Chemical Research and Development, Pfizer)
  • Ian Houson (Technical Project Manager, Continuous Manufacturing and Crystallization, University of Strathclyde)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the leading players providing in the continuous manufacturing services?
  • In which regions are the majority of continuous manufacturers located?
  • What is the installed, global capacity for continuous manufacturing?
  • Which partnership models are commonly adopted by stakeholders engaged in providing continuous manufacturing services?
  • Who are the other key stakeholders (modular facility providers and technology / equipment developers) in this domain?
  • Which factors are likely to influence the evolution of this market?
  • How has the patent landscape evolved over the last several years?
  • Which research institutes have received relatively more grants for projects related to continuous manufacturing?
  • Which organizations have taken significant in-house initiatives in the field of continuous manufacturing?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Chapter Outlines

Chapter 2 provides an executive summary of the key insights captured during our research. It offers a high-level view on the likely evolution of the pharmaceutical and biopharmaceutical continuous manufacturing market in the short to mid-term and long term.

Chapter 3 provides a general introduction to continuous flow chemistry. The chapter also includes the historical evolution of continuous manufacturing in the pharmaceutical industry. It features a brief overview of the regulatory landscape, the early adopters of this technology, advantages and key challenges associated with this technique. The chapter also discusses the future perspective of the pharmaceutical and biopharmaceutical continuous manufacturing market in this domain.

Chapter 4 provides an overview of the market landscape of companies engaged in continuous manufacturing. The chapter features information on year of establishment, company size, purpose of manufacturing (in-house and contract services), scale of operation (preclinical, clinical and commercial), location of headquarters, location of manufacturing facilities, type of drug molecule (biologic and small molecule), type of continuous manufacturing related service offered (process development, API manufacturing, intermediate manufacturing, drug product manufacturing, and packaging and fill / finish), type of dosage form offered (solid and liquid), and installed capacity and batch size (if available).

Chapter 5 features detailed profiles of key North American players engaged in pharmaceutical and biopharmaceutical continuous manufacturing. Each profile presents a brief overview of the company, its overall contract service offerings, continuous manufacturing capabilities and facilities, recent developments and future outlook.

Chapter 6 features detailed profiles of key European players engaged in pharmaceutical and biopharmaceutical continuous manufacturing. Each profile presents a brief overview of the company, its overall contract service offerings, continuous manufacturing capabilities and facilities, recent developments and future outlook.

Chapter 7 features detailed profiles of some of key Asia-Pacific players in pharmaceutical and biopharmaceutical continuous manufacturing. Each profile presents a brief overview of the company, its overall contract service offerings, continuous manufacturing capabilities and facilities, recent developments and future outlook.

Chapter 8 features an elaborate discussion and analysis of the various collaborations established in this market, since 2013. Further, the partnership activities in this domain have been analyzed on the basis of year of agreement, the type of partnership (research agreements, facility development / establishment agreements, technology enhancement agreements, service alliances, process development agreements, manufacturing agreements and other relevant agreements) and geographical location of the players involved in the collaborations. The instances that we came across were analyzed based on various parameters including scale of operation (preclinical, clinical and commercial), type of drug molecule (biologic and small molecule), type of continuous manufacturing related service (API manufacturing, intermediate manufacturing and end product manufacturing) and type of dosage form (solid and liquid).

Chapter 9 features an elaborate discussion on the various expansions that have taken place in this market, since 2013. Further, the expansion initiatives have been analyzed on the basis of year of expansion and the type of expansion (facility / plant expansion, technology installation, technology enhancement and service expansion), geographical location of the facility, scale of operation (preclinical, clinical and commercial), type of drug molecule (biologic and small molecule), type of continuous manufacturing related service (API manufacturing, intermediate manufacturing and end product manufacturing) and type of dosage form (solid and liquid).

Chapter 10 provides a detailed competitiveness analysis of companies having expertise in continuous manufacturing, considering various relevant parameters, such as year of experience (year of establishment - the current year), company size which comes under supplier strength, scale of production (pre-clinical, clinical and commercial) which comes under portfolio strength, type of service(s) (process development, drug substance manufacturing, intermediate manufacturing, final dosage form, packaging and labelling) and regions which comes under service applicability.

Chapter 11 features an estimate of the overall, installed capacity for manufacturing drug substances and drug products based on information reported by industry stakeholders in the public domain, highlighting the distribution of the available capacity on the basis of type of drug molecule (biologic and small molecule), company size (small-sized, mid-sized and large), scale of operation (preclinical, clinical and commercial), location of headquarters (North America, Europe and Asia-Pacific), location of manufacturing facilities (North America, Europe and Asia-Pacific).

Chapter 12 provides information on the various grants that were awarded to research institutes conducting projects related to continuous manufacturing, between 2016 and 2021. The analysis also highlights important parameters associated with grants, such as year of award, type of grant, grant amount, focus area, support period, popular recipient organizations, type of recipient organization, funding institute center, funding mechanism and prominent program officers.

Chapter 13 provides an in-depth patent analysis, presenting an overview on the filed / granted patents related to continuous manufacturing. For this analysis, we looked at the patents that have been published by various players, till 2021. The analysis highlights key details and trends associated with these patents, including patent type, publication year, geographical location, assigned CPC symbol, emerging focus area, type of applicant and leading industry / academic players (in terms of size of intellectual property portfolio). It features a three-dimensional bubble analysis (based on patent citation count, publication year, extended geographical reach) . It also includes a patent benchmarking analysis and a detailed valuation analysis.

Chapter 14 highlights initiatives taken by the leading pharmaceutical companies (in terms of revenues), covering both partnered as well as in-house projects.

Chapter 15 features a review of the companies offering modular facility / modular cleanroom with information on their geographical location (North America, Europe, Asia-Pacific and rest of the world), establishment year, size (small-sized, mid-sized or large) and type of industries served (pharmaceutical, biotechnology or others). It also includes information on the recent projects undertaken by these companies.

Chapter 16 presents a case study on the companies offering technologies / equipment (flow reactors, continuous blenders and mixers, continuous granulators, continuous compressors, continuous coaters, continuous dryers, continuous filtration, distillation and centrifugation equipment, continuous chromatography, PAT technology and other technologies) that can potentially be used in a continuous manner, providing information on the geographical location of potential stakeholders and the type of technology / equipment provided.

Chapter 17 a case study on the roadmap for the adoption of continuous manufacturing technique, discussing different strategies that can be followed by the company in order to adopt this technology or transition from batch manufacturing to continuous manufacturing.

Chapter 18 presents a comprehensive market forecast analysis, highlighting the likely growth of the pharmaceutical and biopharmaceutical continuous manufacturing market, for the time period 2022-2035. In order to provide an informed future outlook, our projections have been segmented on the basis of [A] purpose of manufacturing (in-house and contract services) [B] scale of operation (preclinical, clinical and commercial), [C] type of drug molecule (small molecule and biologic), [D] type of continuous manufacturing related service (API manufacturing and end product manufacturing) and [E] type of dosage form (solid and liquid) and [F] key geographical regions (North America, Europe, Asia-Pacific and rest of the world).

Chapter 19 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 20 is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Andrea Adamo (Founder and Chief Executive Officer, Zaiput Flow Technologies), Bayan Takizawa (Co-Founder and Chief Business Officer, CONTINUUS Pharmaceuticals), Eric Fang (Chief Scientific Officer, Snapdragon Chemistry), Himanshu Gadgil (Director and Chief Scientific Officer, Enzene Biosciences), Nick Thomson (Senior Director Chemical Research and Development, Pfizer) and Ian Houson (Technical Project Manager, Continuous Manufacturing and Crystallization, University of Strathclyde).

Chapter 21 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 22 is an appendix, which contains the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Question Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Historical Evolution of Continuous Manufacturing
  • 3.3. Continuous Manufacturing in the Pharmaceutical Industry
    • 3.3.1. Regulatory Landscape
    • 3.3.2. Early Adopters of Continuous Manufacturing
    • 3.3.3. Anticipated Shift to Continuous Manufacturing
    • 3.3.4. Advantages of Continuous Manufacturing
    • 3.3.5. Key Challenges Associated with Continuous Manufacturing
    • 3.3.6. Future Perspectives

4. MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Companies with Expertise in Continuous Manufacturing: Overall Market Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Purpose of Manufacturing
    • 4.2.4. Analysis by Scale of Operation
    • 4.2.5. Analysis by Location of Headquarters
    • 4.2.6. Analysis by Location of Continuous Manufacturing Facilities
    • 4.2.7. Analysis by Type of Drug Molecule
    • 4.2.8. Analysis by Type of Continuous Manufacturing Related Service
    • 4.2.9. Analysis by Type of Dosage Form
    • 4.2.10. Heat Map: Analysis by Company Size and Location of Headquarters
    • 4.2.11. Information on Production Capacity
    • 4.2.12. Logo Landscape: Analysis by Year of Establishment and Company Size
    • 4.2.13. Grid Representation: Analysis by Scale of Operation, Type of Continuous Manufacturing Related Service and Type of Dosage Form
    • 4.2.14. Geographical Map: Analysis by Location of Continuous Manufacturing Facilities and Type of Drug Molecule

5. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN NORTH AMERICA: PROFILES

  • 5.1. Chapter Overview
  • 5.2. AbbVie Contract Manufacturing
    • 5.2.1. Company Overview
    • 5.2.2. Financial Information
    • 5.2.3. Service Portfolio
    • 5.2.4. Continuous Manufacturing Capabilities and Facilities
    • 5.2.5. Recent Developments and Future Outlook
  • 5.3. Cambrex
    • 5.3.1. Company Overview
    • 5.3.2. Financial Information
    • 5.3.4. Service Portfolio
    • 5.3.5. Continuous Manufacturing Capabilities and Facilities
    • 5.3.6. Recent Developments and Future Outlook
  • 5.4. Patheon (acquired by Thermo Fisher Scientific)
    • 5.4.1. Company Overview
    • 5.4.2. Financial Information
    • 5.4.3. Service Portfolio
    • 5.4.4. Continuous Manufacturing Capabilities and Facilities
    • 5.4.5. Recent Developments and Future Outlook
  • 5.5. SK Pharmteco
    • 5.5.1. Company Overview
    • 5.5.2. Service Portfolio
    • 5.5.3. Continuous Manufacturing Capabilities and Facilities
    • 5.5.4. Recent Developments and Future Outlook
  • 5.6. Colorcon
    • 5.6.1. Company Overview
    • 5.6.2. Service Portfolio
    • 5.6.3. Continuous Manufacturing Capabilities and Facilities
    • 5.6.4. Recent Developments and Future Outlook

6. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN EUROPE: PROFILES

  • 6.1. Chapter Overview
  • 6.2. Ajinomoto Bio-Pharma Service
    • 6.2.1. Company Overview
    • 6.2.2. Financial Information
    • 6.2.3. Service Portfolio
    • 6.2.4. Continuous Manufacturing Capabilities and Facilities
    • 6.2.5. Recent Developments and Future Outlook
  • 6.3. Almac Group
    • 6.3.1. Company Overview
    • 6.3.2. Service Portfolio
    • 6.3.3. Continuous Manufacturing Capabilities and Facilities
    • 6.3.4. Recent Developments and Future Outlook
  • 6.4. Boehringer Ingelheim BioXcellence™
    • 6.4.1. Company Overview
    • 6.4.2. Financial Information
    • 6.4.3. Service Portfolio
    • 6.4.4. Continuous Manufacturing Capabilities and Facilities
    • 6.4.5. Recent Developments and Future Outlook
  • 6.5. CordonPharma
    • 6.5.1. Company Overview
    • 6.5.2. Service Portfolio
    • 6.5.3. Continuous Manufacturing Capabilities and Facilities
    • 6.5.4. Recent Developments and Future Outlook
  • 6.6. GEA Group
    • 6.6.1. Company Overview
    • 6.6.2. Financial Information
    • 6.6.3. Service portfolio
    • 6.6.4. Continuous Manufacturing Capabilities and Facilities
    • 6.6.5. Recent Developments and Future Outlook
  • 6.7. Glatt Group
    • 6.7.1. Company Overview
    • 6.7.2. Service Portfolio
    • 6.7.3. Continuous Manufacturing Capabilities and Facilities
    • 6.7.4. Recent Developments and Future Outlook
  • 6.8. Hovione
    • 6.8.1. Company Overview
    • 6.8.2. Service Portfolio
    • 6.8.3. Continuous Manufacturing Capabilities and Facilities
    • 6.8.4. Recent Developments and Future Outlook
  • 6.9. Lonza
    • 6.9.1. Company Overview
    • 6.9.2. Financial Information
    • 6.9.3. Service Portfolio
    • 6.9.4. Continuous Manufacturing Capabilities and Facilities
    • 6.9.5. Recent Developments and Future Outlook

7. COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING IN ASIA-PACIFIC: PROFILES

  • 7.1. Chapter Overview
  • 7.2. ACG Group
    • 7.2.1. Company Overview
    • 7.2.2. Financial Information
    • 7.2.3. Service Portfolio
    • 7.2.4. Continuous Manufacturing Capabilities and Facilities
    • 7.2.5. Recent Developments and Future Outlook
  • 7.3. Aurobindo Pharma
    • 7.3.1. Company Overview
    • 7.3.2. Financial Information
    • 7.3.3. Service Portfolio
    • 7.3.4. Continuous Manufacturing Capabilities and Facilities
    • 7.3.5. Recent Developments and Future Outlook
  • 7.4. Kaneka
    • 7.4.1. Company Overview
    • 7.4.2. Financial Information
    • 7.4.3. Service Portfolio
    • 7.4.4. Continuous Manufacturing Capabilities and Facilities
    • 7.4.5. Recent Developments and Future Outlook
  • 7.5. WuXi AppTec
    • 7.5.1. Company Overview
    • 7.5.2. Financial Information
    • 7.5.3. Service Portfolio
    • 7.5.4. Continuous Manufacturing Capabilities and Facilities
    • 7.5.5. Recent Developments and Future Outlook

8. COMPANY COMPETITIVENESS ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Key Parameters and Methodology
  • 8.3. Company Competitiveness Analysis
  • 8.4. Competitiveness Analysis: Companies providing continuous manufacturing services in North America
  • 8.5. Competitiveness Analysis: Companies providing continuous manufacturing services in Europe
  • 8.6. Competitiveness Analysis: Companies providing continuous manufacturing services in Asia-Pacific

9. RECENT PARTNERSHIPS AND COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. List of Partnerships and Collaborations
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Scale of Operation
    • 9.3.4. Analysis by Type of Drug Molecule
    • 9.3.5. Analysis by Type of Continuous Manufacturing Related Service
    • 9.3.6. Analysis by Type of Dosage Form
    • 9.3.7. Most Active Players: Analysis by Number of Partnerships
    • 9.3.8. Regional Analysis
      • 9.3.8.1. Intercontinental and Intracontinental Agreements

10. RECENT EXPANSIONS

  • 10.1. Chapter Overview
  • 10.2. Recent Expansions
    • 10.2.1. Analysis by Year of Expansion
    • 10.2.2. Analysis by Type of Expansion
    • 10.2.3. Analysis by Scale of Operation
    • 10.2.4. Analysis by Type of Drug Molecule
    • 10.2.5. Analysis by Type of Continuous Manufacturing Related Service
    • 10.2.6. Analysis by Type of Dosage Form
    • 10.2.7. Most Active Players: Analysis by Number of Expansions
    • 10.2.8. Regional Analysis
      • 10.2.8.1. Analysis by Location of Expansion Project

11. CAPACITY ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Assumptions and Methodology
  • 11.3. Global, Continuous Manufacturing Capacity for Small Molecule APIs
    • 11.3.1. Analysis by Company Size
    • 11.3.2. Analysis by Purpose of Manufacturing
    • 11.3.3. Analysis by Scale of Operation
    • 11.3.4. Analysis by Location of Headquarters
    • 11.3.4. Analysis by Location of Continuous Manufacturing Facilities
  • 11.4. Global, Continuous Manufacturing Capacity for Small Molecule End Products
    • 11.4.1. Analysis by Company Size
    • 11.4.2. Analysis by Purpose of Manufacturing
    • 11.4.3. Analysis by Scale of Operation
    • 11.4.4. Analysis by Location of Headquarters
    • 11.4.5. Analysis by Location of Continuous Manufacturing Facilities
  • 11.5. Global, Continuous Manufacturing Capacity for Biologics
    • 11.5.1. Analysis by Company Size
    • 11.5.2. Analysis by Purpose of Manufacturing
    • 11.5.3. Analysis by Scale of Operation
    • 11.5.4. Analysis by Location of Headquarters
    • 11.5.5. Analysis by Location of Continuous Manufacturing Facilities

12. ACADEMIC GRANT ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Scope and Methodology
  • 12.3. Continuous Manufacturing: List of Academic Grants
    • 12.3.1. Analysis by Number of Grants
    • 12.3.2. Analysis by Activity Code
    • 12.3.3. Analysis by Grant Amount
    • 12.3.4. Analysis by Focus Area
    • 12.3.5. Analysis by Support Period
    • 12.3.6 Popular Recipient Organizations: Analysis by Number of Grants
    • 12.3.7 Analysis by Type of Recipient Organization
    • 12.3.8. Analysis by Funding Institute Center
    • 12.3.9. Analysis by Funding Mechanism
    • 12.3.10. Prominent Program Officers: Analysis by Number of Grants

13. PATENT ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Scope and Methodology
  • 13.3. Continuous Manufacturing: Patent Analysis
    • 13.3.1. Analysis by Publication Year
    • 13.3.2. Analysis by Geography
    • 13.3.3. Analysis by CPC Symbols
    • 13.3.4. Emerging Focus Areas
    • 13.3.5. Analysis by Type of Applicant
    • 13.3.6. Leading Players: Analysis by Number of Patents
    • 13.3.7. Continuous Manufacturing: Three-Dimensional Bubble Analysis
    • 13.3.8. Continuous Manufacturing: Patent Valuation Analysis
      • 13.3.8.1. Leading Patents: Information by Number of Citations

14. INITIATIVES OF COMPANIES WITH IN-HOUSE CONTINUOUS MANUFACTURING CAPABILITIES

  • 14.1. Chapter Overview
  • 14.2. Continuous Manufacturing Initiatives of Leading Companies
    • 14.2.1. AbbVie
      • 14.2.1.1. Partnered Initiatives
      • 14.2.1.2. In-House Initiatives
    • 14.2.2. Amgen
      • 14.2.2.1. Partnered Initiatives
      • 14.2.2.2. In-House Initiatives
    • 14.2.3. Bristol-Myers Squibb
      • 14.2.3.1. Partnered Initiatives
      • 14.2.3.2. In-House Initiatives
    • 14.2.4. GlaxoSmithKline
      • 14.2.4.1. Partnered Initiatives
      • 14.2.4.2. In-House Initiatives
    • 14.2.5. Merck
      • 14.2.5.1. Partnered Initiatives
      • 14.2.5.2. In-House Initiatives
    • 14.2.6. Novartis
      • 14.2.6.1. Partnered Initiatives
      • 14.2.6.2. In-House Initiatives
    • 14.2.7. Pfizer
      • 14.2.7.1. Partnered Initiatives
      • 14.2.7.2. In-House Initiatives
    • 14.2.8. Roche
      • 14.2.8.1. Partnered Initiatives
      • 14.2.8.2. In-House Initiatives
    • 14.2.9. Sanofi
      • 14.2.9.1. Partnered Initiatives
      • 14.2.9.2. In-House Initiatives

15. CASE STUDY: MODULAR FACILITIES IN PHARMACEUTICAL / BIOTECHNOLOGY INDUSTRY

  • 15.1. Chapter Overview
  • 15.2. Historical Background
  • 15.3. Concept of Modularization
    • 15.3.1. Types of Modules
    • 15.3.2. Modular Construction Process
  • 15.4. Modular Construction in the Pharmaceutical Industry
    • 15.4.1. Advantages of Modular Construction in the Pharmaceutical Industry
  • 15.5. Modular Facility Manufacturers
    • 15.5.1. Distribution by Industry Served
    • 15.5.2. Distribution by Geography
    • 15.5.3. Modular Projects Executed / Undertaken
  • 15.6. Modular Pharmaceutical Cleanrooms
    • 15.6.1. Cleanroom Classification and Current Standards
    • 15.6.2. Advantages of Modular Cleanrooms
    • 15.6.3. Regulations and Standards Concerning Modular Cleanroom Construction
  • 15.7. Modular Cleanroom Providers
    • 15.7.1. Distribution by Industry Served
    • 15.7.2. Distribution by Geography
    • 15.7.3. Type of Modular Cleanrooms Offered

16. CASE STUDY: TECHNOLOGY AND EQUIPMENT PROVIDERS

  • 16.1. Chapter Overview
  • 16.2. Types of Continuous Manufacturing Technologies
  • 16.3. Equipment and Technologies for Continuous Manufacturing Small Molecules and Biologics
    • 16.3.1. Continuous Blending and Mixing Equipment
    • 16.3.2. Continuous Granulating Equipment
    • 16.3.3. Continuous Drying Equipment
    • 16.3.4. Continuous Compression Equipment
    • 16.3.5. Continuous Coating Equipment
    • 16.3.6. Continuous Filtration, Continuous Distillation and Continuous Centrifugation Equipment
    • 16.3.7. Continuous Chromatography Equipment
    • 16.3.8. Continuous Reactors / Bioreactors
    • 16.3.9. Full Line Continuous Platforms
    • 16.3.10. Process Analytical Technologies
    • 16.3.11. Other Technologies
  • 16.4. Logo Landscape: Analysis of Technology Providers by Number and Type of Equipment

17. CASE STUDY: ROADMAP FOR THE ADOPTION OF CONTINUOUS MANUFACTURING PROCESSES

  • 17.1. Chapter Overview
  • 17.2. Key Strategies for the Adoption of Continuous Manufacturing Processes
    • 17.2.1. Phase I: Process Development and Implementation
    • 17.2.2. Phase II: Equipment / Technology Development and Installation
    • 17.2.3. Phase III: Facility / Plant Development and Establishment
    • 17.2.4. Phase IV: Product Development and Manufacturing

18. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 18.1. Chapter Overview
  • 18.2. Forecast Methodology and Key Assumptions
  • 18.3. Overall, Continuous Manufacturing Market, 2022-2035
    • 18.3.1. Continuous Manufacturing Market: Distribution by Purpose of Manufacturing, 2022-2035
    • 18.3.2. Continuous Manufacturing Market: Distribution by Scale of Operation, 2022-2035
    • 18.3.3. Continuous Manufacturing Market: Distribution by Type of Drug Molecule, 2022-2035
    • 18.3.4. Continuous Manufacturing Market: Distribution by Type of Continuous Manufacturing Related Service, 2022-2035
    • 18.3.5. Continuous Manufacturing Market: Distribution by Type of Dosage Form, 2022-2035
    • 18.3.6. Continuous Manufacturing Market: Distribution by Key Geographical Regions, 2022-2035
  • 18.4. Continuous Manufacturing Market for Small Molecule Drugs, 2022-2035
    • 18.4.1. Distribution by Purpose of Manufacturing, 2022-2035
    • 18.4.2. Distribution by Scale of Operation, 2022-2035
    • 18.4.3. Distribution by Type of Continuous Manufacturing Related Service, 2022-2035
    • 18.4.4. Distribution by Key Geographical Regions, 2022-2035
  • 18.5. Continuous Manufacturing Market for Biologics, 2022-2035
    • 18.5.1. Distribution by Purpose of Manufacturing, 2022-2035
    • 18.5.2. Distribution by Scale of Operation, 2022-2035
    • 18.5.3. Distribution by Type of Continuous Manufacturing Related Service, 2022-2035
    • 18.5.4. Distribution by Key Geographical Regions, 2022-2035

19. CONCLUSION

  • 19.1. Chapter Overview

20. EXECUTIVE INSIGHTS

  • 20.1. Chapter Overview
  • 20.2. Zaiput Flow Technologies
    • 20.2.1. Company Snapshot
    • 20.2.2. Interview Transcript: Andrea Adamo, Founder and Chief Executive Officer
  • 20.3. CONTINUUS Pharmaceuticals
    • 20.3.1. Company Snapshot
    • 20.3.2. Interview Transcript: Bayan Takizawa, Co-Founder and Chief Business Officer
  • 20.4. Snapdragon Chemistry
    • 20.4.1. Company Snapshot
    • 20.4.2. Interview Transcript: Eric Fang, Chief Scientific Officer
  • 20.5. Enzene Biosciences
    • 20.5.1. Company Snapshot
    • 20.5.2. Interview Transcript: Himanshu Gadgil, Director and Chief Scientific Officer
  • 20.6. Pfizer
    • 20.6.1. Company Snapshot
    • 20.6.2. Interview Transcript: Nick Thomson, Senior Director Chemical Research and Development
  • 20.7. University of Strathclyde
    • 20.7.1. Company Snapshot
    • 20.7.2. Interview Transcript: Ian Houson, Technical Project Manager

21. APPENDIX 1: TABULATED DATA

22. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 4.1 Continuous Drug Manufacturers: Distribution by Year of Establishment
  • Figure 4.2 Continuous Drug Manufacturers: Distribution by Company Size
  • Figure 4.3 Continuous Drug Manufacturers: Distribution by Purpose of Manufacturing
  • Figure 4.4 Continuous Drug Manufacturers: Distribution by Scale of Operation
  • Figure 4.5 Continuous Drug Manufacturers: Distribution by Location of Headquarters
  • Figure 4.6 Continuous Drug Manufacturers: Distribution by Location of Continuous Manufacturing Facilities
  • Figure 4.7 Continuous Drug Manufacturers: Distribution by Type of Drug Molecule
  • Figure 4.8 Continuous Drug Manufacturers: Distribution by Type of Continuous Manufacturing Related Service
  • Figure 4.9 Continuous Drug Manufacturers: Distribution by Type of Dosage Form
  • Figure 4.10 Continuous Drug Manufacturers: Distribution by Year of Establishment and Type of Company Size
  • Figure 4.11 Continuous Drug Manufacturers: Distribution by Scale of Operation, Type of Continuous Manufacturing related Service Offered and Type of Dosage Form
  • Figure 4.12 Continuous Drug Manufacturers: Distribution by Location of Continuous Manufacturing Facility and Type of Drug Molecule Manufactured
  • Figure 5.1 AbbVie: Annual Revenues, 2014-2021 (USD Billion)
  • Figure 5.2 AbbVie Contract Manufacturing: Services Portfolio
  • Figure 5.3 Cambrex: Annual Revenues, 2014 - 9M 2019 (USD Million)
  • Figure 5.4 Cambrex: Services Portfolio
  • Figure 5.5 Thermo Fisher Scientific: Annual Revenues, 2014 - H1 2021 (USD Million)
  • Figure 5.7 SK Pharmteco: Service Portfolio
  • Figure 5.8. Colorcon: Service Portfolio
  • Figure 6.1 Ajinomoto Bio-Pharma Services: Annual Revenues, FY 2014 - FY 2021 (JPY Billion)
  • Figure 6.2 Ajinomoto Bio-Pharma Service: Services Portfolio
  • Figure 6.3 Almac: Service Portfolio
  • Figure 6.4 Boehringer Ingelheim: Annual Revenues, 2014- H1 2021 (EUR Billion)
  • Figure 6.5 Boehringer Ingelheim BioXcellence: Service Portfolio
  • Figure 6.7 Hovione: Service Portfolio
  • Figure 6.8 Lonza: Annual Revenues, 2014-2021 (CHF Billion)
  • Figure 6.9 Lonza: Service Portfolio
  • Figure 6.10 Glatt Pharma: service Portfolio
  • Figure 6.11 GEA Group: Annual Revenues, FY 2014 - Q1 2021 (EURP Million)
  • Figure 6.12 GEA Group: Service Portfolio
  • Figure 7.1 Kaneka: Annual Revenues, FY 2014 - Q1 2021 (JPY Billion)
  • Figure 7.2 Kaneka: Service Portfolio
  • Figure 7.3 WuXi AppTec: Annual Revenues, 2015 - H1 2021 (RMB Million)
  • Figure 7.4 WuXi Biologics: Service Portfolio
  • Figure 7.5 STA Pharmaceuticals: Service Portfolio
  • Figure 7.6. ACG Group: Annual Revenues, FY 2014 - Q1 2021 (YEN Million)
  • Figure 7.7 ACG Group: Service Portfolio
  • Figure 7.8 Aurobindo Pharma: Annual Revenues, FY 2014 - FY 2021
  • Figure 7.9 Aurobindo Pharma: Service Portfolio
  • Figure 8.1 Company Competitiveness Analysis: Continuous Manufacturing Service in North America
  • Figure 8.2 Company Competitiveness Analysis: Continuous Manufacturing Service in Europe
  • Figure 8.3 Company Competitiveness Analysis: Continuous Manufacturing Service in Asia Pacific
  • Figure 9.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2013-2021
  • Figure 9.2. Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 9.3. Partnerships and Collaborations: Year-wise Trend by Type of Partnership 2013-2021
  • Figure 9.4. Partnerships and Collaborations: Distribution by Type of Partnership, 2013-2015 and 2016-2021
  • Figure 9.5. Partnerships and Collaborations: Distribution by Scale of Operation
  • Figure 9.6. Partnerships and Collaborations: Distribution by Type of Drug Molecule
  • Figure 9.7. Partnerships and Collaborations: Distribution Type of Continuous Manufacturing Related Service
  • Figure 9.8. Partnerships and Collaborations: Distribution by Type of Dosage Form
  • Figure 9.9. Most Active Players: Distribution by Number of Partnerships
  • Figure 9.10. Partnerships and Collaborations: Regional Distribution
  • Figure 9.11. Partnerships and Collaborations: Intercontinental and IntracontinentalAgreements
  • Figure 10.1. Recent Expansions: Cumulative Year-wise Trend, 2013- November 2021
  • Figure 10.2. Recent Expansions: Distribution by Type of Expansion
  • Figure 10.3. Recent Expansions: Distribution by Scale of Operation and Year of Expansion Figure 10.4.Recent Expansions: Distribution by Type of Drug Molecule
  • Figure 10.5. Recent Expansions: Distribution by Type of Continuous Manufacturing Related Service
  • Figure 10.6. Recent Expansions: Distribution by Type of Dosage Form
  • Figure 10.7. Most Active Players: Distribution by Number of Expansions
  • Figure 10.8. Recent Expansions: Intercontinental and Intracontinental Distribution
  • Figure 10.9. Recent Expansions: Regional Distribution
  • Figure 11.1 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Geographical Location
  • Figure 11.2 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Company Size (Range of Capacity)
  • Figure 11.3 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Company Size (in Metric Tonnes / Year)
  • Figure 11.4 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Purpose of Manufacturing (in Metric Tonnes / Year)
  • Figure 11.5 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Scale of Operation (in Metric Tonnes / Year)
  • Figure 11.6 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Location of Headquarters (in Metric Tonnes / Year)
  • Figure 11.7 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Location of Continuous Manufacturing Facilities (in Metric Tonnes / Year)
  • Figure 11.8 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Geographical Location
  • Figure 11.9 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Company Size (Range of Capacity)
  • Figure 11.10 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Company Size (in Kgs / Year)
  • Figure 11.11 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Purpose of Manufacturing (in Kgs / Year)
  • Figure 11.12 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Scale of Operation (in Kgs / Year)
  • Figure 11.13 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Location of Headquarters (in Kgs / Year)
  • Figure 11.14 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Location of Continuous Manufacturing Facilities (in Kgs / Year)
  • Figure 11.15 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Geographical Location
  • Figure 11.16 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Company Size (Range of Capacity)
  • Figure 11.17 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Company Size (in Kgs / Year)
  • Figure 11.18 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Purpose of Manufacturing (in Kgs / Year)
  • Figure 11.19 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Scale of Operation (in Kgs / Year)
  • Figure 11.20 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Location of Headquarters (in Kgs / Year)
  • Figure 11.21 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Location of Continuous Manufacturing Facilities (in Kgs / Year)
  • Figure 12.1 Academic Grant Analysis: Cumulative Year-wise Trend, 2014-2019
  • Figure 12.2 Academic Grant Analysis: Distribution by Activity Codes
  • Figure 12.3 Academic Grant Analysis: Year-wise Distribution by Leading Activity Codes
  • Figure 12.4 Academic Grant Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
  • Figure 12.5 Academic Grant Analysis: Distribution by Focus Areas
  • Figure 12.6 Academic Grant Analysis: Distribution by Support Period
  • Figure 12.7 Popular Recipient Organizations: Distribution by States in the US
  • Figure 12.8 Popular Recipient Organizations: Distribution by Number of Grants
  • Figure 12.9 Popular Recipient Organizations: Distribution by Amount Awarded
  • Figure 12.10 Academic Grant Analysis: Distribution by Type of Recipient Organization
  • Figure 12.11 Academic Grant Analysis: Distribution by Support Year and Funding Institute Centre
  • Figure 12.12 Academic Grant Analysis: Distribution by Funding Mechanism
  • Figure 12.13 Prominent Program Officers: Distribution by Number of Grants
  • Figure 13.1 Patent Portfolio: Distribution by Type of Patent
  • Figure 13.2 Patent Portfolio: Cumulative Year-wise Trend, till 2019
  • Figure 13.3 Patent Portfolio: Cumulative Year-wise Trend, till 2021 (forPharmaceutical and Biopharmaceutical Industry)
  • Figure 13.4 Patent Portfolio: Distribution by Geography
  • Figure 13.5 Patent Portfolio: Distribution by CPC Symbols
  • Figure 13.6 Patent Portfolio: Distribution of CPC Symbols by Publication Year
  • Figure 13.7 Patent Portfolio: Emerging Focus Areas
  • Figure 13.8 Patent Portfolio: Distribution by Type of Applicant
  • Figure 13.9 Leading Industry Players: Distribution by Number of Patents
  • Figure 13.10 Leading Non-Industry Players: Distribution by Number of Patents
  • Figure 13.11 Patent Portfolio: Three-Dimensional Bubble Analysis
  • Figure 13.12 Patent Portfolio: Distribution by Patent Age, 2000-2021
  • Figure 13.13 Patent Portfolio: Distribution by Geography, Before 2014-2021
  • Figure 13.14 Patent Portfolio: Valuation Analysis
  • Figure 14.1 Continuous Manufacturing Initiatives: AbbVie
  • Figure 14.2 Continuous Manufacturing Initiatives: Amgen
  • Figure 14.3 Continuous Manufacturing Initiatives: Bristol-Myers Squibb
  • Figure 14.4 Continuous Manufacturing Initiatives: GlaxoSmithKline
  • Figure 14.5 Continuous Manufacturing Initiatives: Merck
  • Figure 14.6 Continuous Manufacturing Initiatives: Novartis
  • Figure 14.7 Continuous Manufacturing Initiatives: Pfizer
  • Figure 14.8 Continuous Manufacturing Initiatives: Roche
  • Figure 14.9 Continuous Manufacturing Initiatives: Sanofi
  • Figure 15.1 Modular Construction: Applications
  • Figure 15.2 Modular Construction: Processes Involved
  • Figure 15.3 Modular and Conventional Buildings: Construction Timelines
  • Figure 15.4 Modular Construction: Advantages
  • Figure 15.5 Modular Facility Manufacturers: Distribution by Geography
  • Figure 15.6 Modular Cleanroom Providers: Distribution by Geography
  • Figure 16.1 Type of Continuous Manufacturing Technologies: Hybrid vs Fully Integrated Continuous Technologies
  • Figure 16.2 Logo Landscape: Distribution of Technology / Equipment Providers by Number and Type of Equipment / Technology
  • Figure 17.1 Continuous Manufacturing: Key Strategies for the Adoption of Continuous Manufacturing Processes
  • Figure 17.2 Process Development and Implementation (Phase I): Distribution by Type of Strategies Adopted
  • Figure 17.3 Equipment / Technology Development and Installation (Phase II): Distribution by the Type of Strategies Adopted
  • Figure 17.4 Facility / Plant Development and Establishment (Phase III): Distribution by the Type of Strategies Adopted
  • Figure 17.5 Product Development and Manufacturing (Phase IV): Distribution by the Type of Strategies Adopted
  • Figure 18.1 Continuous Manufacturing, 2022-2035: Standard Adoption Curve
  • Figure 18.2. Overall, Continuous Manufacturing Market, 2022-2035 (USD Million)
  • Figure 18.3. Continuous Manufacturing Market: Distribution by Purpose of Manufacturing, 2022-2035 (USD Million)
  • Figure 18.4. Continuous Manufacturing Market: Distribution by Scale of Operation, 2022-2035 (USD Million)
  • Figure 18.5. Continuous Manufacturing Market: Distribution by Type of Drug Molecule, 2022-2035 (USD Million)
  • Figure 18.6. Continuous Manufacturing Market: Distribution by Type of Continuous Manufacturing Related Service, 2022-2035 (USD Million)
  • Figure 18.7. Continuous Manufacturing Market: Distribution by Type of Dosage Form, 2022-2035 (USD Million)
  • Figure 18.8. Continuous Manufacturing Market: Distribution by Geographical Regions 2022-2035 (USD Million)
  • Figure 18.9 Continuous Manufacturing Market for Small Molecules: Distribution by Purpose of Manufacturing, 2022-2035 (USD Million)
  • Figure 18.10 Continuous Manufacturing Market for Small Molecule: Distribution by Scale of Operation, 2022-2035 (USD Million)
  • Figure 18.11 Continuous Manufacturing Market for Small Molecule: Distribution by Type of Continuous Manufacturing Related Service, 2022-2035 (USD Million)
  • Figure 18.12 Continuous Manufacturing Market for Small Molecule: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
  • Figure 18.13 Continuous Manufacturing Market for Biologic: Distribution by Purpose of Manufacturing, 2022-2035 (USD Million)
  • Figure 18.14 Continuous Manufacturing Market for Biologic: Distribution by Scale of Operation, 2022-2035 (USD Million)
  • Figure 18.15 Continuous Manufacturing Market for Biologic: Distribution by Type of Continuous Manufacturing Related Service, 2022-2035 (USD Million)
  • Figure 18 .16 Continuous Manufacturing Market for Biologic: Distribution by Key Geographical Regions, 2022-2035 (USD Million)

List Of Tables

  • Table 3.1 Comparison of Characteristics: Batch Manufacturing Technique and Continuous Manufacturing Technique
  • Table 4.1 List of Companies with Expertise in Continuous Drug Manufacturing
  • Table 4.2 Continuous Drug Manufacturers: Information on Location and Number of Continuous Drug Manufacturing Facilities
  • Table 4.3 Continuous Drug Manufacturers: Information on Type of Drug Molecule
  • Table 4.4 Continuous Drug Manufacturers: Information on Type of Continuous Manufacturing Related Service
  • Table 4.5 Continuous Drug Manufacturers: Information on Type of Dosage Form
  • Table 4.6 Continuous Drug Manufacturers: Distribution by Company Size and Location of Headquarters
  • Table 4.7 Continuous Drug Manufacturers: Information on Production Capacity
  • Table 5.1 Companies profiled in North America
  • Table 5.2 AbbVie: Company Snapshot
  • Table 5.3 AbbVie Contract Manufacturing: Continuous Manufacturing Facilities
  • Table 5.4 AbbVie Contract Manufacturing: Continuous Manufacturing Capabilities
  • Table 5.5 AbbVie Contract Manufacturing: Recent Developments and Future Outlook
  • Table 5.6 Cambrex: Company Snapshot
  • Table 5.7 Cambrex: Continuous Manufacturing Facilities
  • Table 5.8 Cambrex: Continuous Manufacturing Capabilities
  • Table 5.9 Cambrex: Recent Developments and Future Outlook
  • Table 5.10 Patheon: Company Snapshot
  • Table 5.11 Patheon: Continuous Manufacturing Facilities
  • Table 5.12 Patheon: Continuous Manufacturing Capabilities
  • Table 5.13 Thermo Fisher Scientific: Recent Developments and Future Outlook
  • Table 5.14 SK Pharmteco: Company Snapshot
  • Table 5.15 SK Pharmteco: Continuous Manufacturing Facilities
  • Table 5.16 SK Pharmteco: Continuous Manufacturing Capabilities
  • Table 5.17 SK Pharmteco: Recent Developments and Future Outlook
  • Table 5.18 Colorcon: Company Overview
  • Table 5.19 Colorcon: Continuous Manufacturing Facilities
  • Table 5.20 Colorcon: Continuous Manufacturing Capabilities
  • Table 5.21 Colorcon: Recent Developments and Future Outlook
  • Table 6.1 Companies Profiled in Europe
  • Table 6.2 Ajinomoto Bio-Pharma Services: Company Snapshot
  • Table 6.3 Ajinomoto Bio-Pharma Services: Continuous Manufacturing Facilities
  • Table 6.4 Ajinomoto Bio-Pharma Services: Continuous Manufacturing Capabilities
  • Table 6.5 Ajinomoto Bio-Pharma Services: Recent Developments and Future Outlook
  • Table 6.6 Almac: Company Snapshot
  • Table 6.7 Almac: Continuous Manufacturing Facilities
  • Table 6.8 Almac: Continuous Manufacturing Capabilities
  • Table 6.9 Almac: Recent Developments and Future Outlook
  • Table 6.10 Boehringer Ingelheim BioXcellence™: Company Snapshot
  • Table 6.11 Boehringer Ingelheim BioXcellence™: Continuous Manufacturing Facilities
  • Table 6.12 Boehringer Ingelheim BioXcellence™: Continuous Manufacturing Capabilities
  • Table 6.13 Boehringer Ingelheim BioXcellence™: Recent Developments and Future Outlook
  • Table 6.14 CordonPharma: Company Snapshot
  • Table 6.15 CordonPharma: Continuous Manufacturing Facilities
  • Table 6.16 CordonPharma: Continuous Manufacturing Capabilities
  • Table 6.17 CordonPharma: Recent Developments and Future Outlook
  • Table 6.18 Hovione: Company Snapshot
  • Table 6.19 Hovione: Continuous Manufacturing Facilities
  • Table 6.20 Hovione: Continuous Manufacturing Capabilities
  • Table 6.21 Hovione: Recent Developments and Future Outlook
  • Table 6.22 Lonza: Company Snapshot
  • Table 6.23 Lonza: Continuous Manufacturing Facilities
  • Table 6.24 Lonza: Continuous Manufacturing Capabilities
  • Table 6.25 Lonza: Recent Developments and Future Outlook
  • Table 6.22 Glatt Pharma: Company Snapshot
  • Table 6.23 Glatt Pharma: Continuous Manufacturing Facilities
  • Table 6.24 Glatt Pharma: Continuous Manufacturing Capabilities
  • Table 6.25 Glatt Pharma: Recent Developments and Future Outlook
  • Table 6.22 GEA Group: Company Snapshot
  • Table 6.23 GEA Group: Continuous Manufacturing Capabilities
  • Table 6.24 GEA Group: Recent Developments and Future Outlook
  • Table 7.1 Companies Profiled in Asia-Pacific
  • Table 7.2 Kaneka: Company Snapshot
  • Table 7.3 Kaneka: Continuous Manufacturing Facilities
  • Table 7.4 Kaneka: Continuous Manufacturing Capabilities
  • Table 7.5 Kaneka: Recent Developments and Future Outlook
  • Table 7.6 WuXi Biologics: Company Overview
  • Table 7.7 STA Pharmaceuticals: Company Overview
  • Table 7.8 WuXi Biologics: Continuous Manufacturing Facilities
  • Table 7.9 WuXi Biologics: Continuous Manufacturing Capabilities
  • Table 7.10 STA Pharmaceuticals: Continuous Manufacturing Facilities
  • Table 7.11 STA Pharmaceuticals: Continuous Manufacturing Capabilities
  • Table 7.12 WuXi Apptec: Future Outlook
  • Table 7.13 ACG Group: Company Snapshot
  • Table 7.14 ACG Group: Continuous Manufacturing Facilities
  • Table 7.15 ACG Group: Continuous Manufacturing Capabilities
  • Table 7.16 ACG Group: Recent Developments and Future Outlook
  • Table 7.17 Aurobindo Pharma: Company Snapshot
  • Table 7.18 Aurobindo Pharma: Continuous Manufacturing Facilities
  • Table 7.19 Aurobindo Pharma: Continuous Manufacturing Capabilities
  • Table 7.20 Aurobindo Pharma: Recent Developments and Future Outlook
  • Table 8.1 Continuous Manufacturing: List of Partnerships and Collaborations, 2013-2021
  • Table 8.2 Continuous Manufacturing: Information on Scale of Production, Type of Drug Molecule, Continuous Manufacturing Related Services and Type of Drug Product, 2013- 2021
  • Table 9.1 Continuous Manufacturing: List of Recent Expansions, 2013 - November 2021
  • Table 9.2 Continuous Manufacturing: Information on Scale of Production, Type of Drug Molecule, Continuous Manufacturing Related Services and Type of Drug Product, 2013 - November 2021
  • Table 10.1 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Average Capacity by Company Size (Sample Data Set)
  • Table 10.2 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Average Capacity by Company Size (Sample Data Set)
  • Table 10.3 Global, Overall Continuous Manufacturing Capacity for Biologics (Kgs / Year): Average Capacity by Company Size (Sample Data Set)
  • Table 11.1 Continuous Manufacturing: List of Academic Grants, 2014-2021
  • Table 12.1 Patent Portfolio: CPC Symbols
  • Table 12.2 Patent Portfolio: Most Popular CPC Symbols
  • Table 12.3 Patent Portfolio: List of Top CPC symbols
  • Table 12.4 Patent Valuation Analysis: Categorization based on Proprietary Scoring Criteria
  • Table 12.5 Patent Portfolio: Distribution by Number of Citations
  • Table 13.1 AbbVie: Partnered Initiatives
  • Table 13.2 AbbVie: In-House Initiatives
  • Table 13.3 Amgen: Partnered Initiatives
  • Table 13.4 Amgen: In-House Initiatives
  • Table 13.5 Bristol-Myers Squibb: Partnered Initiatives
  • Table 13.6 Bristol-Myers Squibb: In-House Initiatives
  • Table 13.7 GlaxoSmithKline: Partnered Initiatives
  • Table 13.8 GlaxoSmithKline: In-House Initiatives
  • Table 13.9 Merck: Partnered Initiatives
  • Table 13.10 Merck: In-House Initiatives
  • Table 13.11 Novartis: Partnered Initiatives
  • Table 13.12 Novartis: In-House Initiatives
  • Table 13.13 Pfizer: Partnered Initiatives
  • Table 13.14 Pfizer: In-House Initiatives
  • Table 13.15 Roche: Partnered Initiatives
  • Table 13.16 Roche: In-House Initiatives
  • Table 13.17 Sanofi: Partnered Initiatives
  • Table 13.18 Sanofi: In-House Initiatives
  • Table 14.1 List of Modular Facility Manufacturers
  • Table 14.2 Modular Facility Manufacturers: Information on Type of Industry Served
  • Table 14.3 Modular Facility Manufacturers: Modular Projects Executed / Undertaken
  • Table 14.4 Cleanrooms Classification Standards
  • Table 14.5 ISO and FED STD 209E: Cleanroom Classification
  • Table 14.6 List of Modular Cleanroom Providers
  • Table 14.7 Modular Cleanroom Providers: Information on Type of Industry Served
  • Table 14.8 Modular Cleanroom Providers: Information on Type of Modular Cleanroom Offered
  • Table 15.1 Technology and Equipment Providers: List of Continuous Blending and Mixing Equipment
  • Table 15.2 Technology and Equipment Providers: List of Continuous Granulating Equipment
  • Table 15.3 Technology and Equipment Providers: List of Continuous Drying Equipment
  • Table 15.4 Technology and Equipment Providers: List of Continuous Compression Equipment
  • Table 15.5 Technology and Equipment Providers: List of Continuous Coating Equipment
  • Table 15.6 Technologies and Equipment Providers: List of Continuous Filtration, Distillation and Centrifugation Equipment
  • Table 15.7 Technologies and Equipment Providers: List of Continuous Chromatography Equipment
  • Table 15.8 Technologies and Equipment Providers: List of Continuous Flow Reactors / Bioreactors
  • Table 15.9 Technology and Equipment Providers: List of Full Line Continuous Platforms
  • Table 15.10 Technology and Equipment Providers: List of Process Analytical Technologies
  • Table 15.11 Technology and Equipment Providers: List of Other Technologies
  • Table 18.1 Continuous Manufacturing Market: Key Takeaways
  • Table 19.1 Zaiput Flow Technologies: Key Highlights
  • Table 19.2 CONTINUUS Pharmaceuticals: Key Highlights
  • Table 19.3 Snapdragon Chemistry: Key Highlights
  • Table 19.4 Enzene Biosciences: Key Highlights
  • Table 19.5 Pfizer: Key Highlights
  • Table 19.6 University of Strathclyde: Key Highlights
  • Table 20.1 Continuous Drug Manufacturers: Distribution by Year of Establishment
  • Table 20.2 Continuous Drug Manufacturers: Distribution by Company Size
  • Table 20.3 Continuous Drug Manufacturers: Distribution by Purpose of Manufacturing
  • Table 20.4 Continuous Drug Manufacturers: Distribution by Scale of Operation
  • Table 20.5 Continuous Drug Manufacturers: Distribution by Location of Headquarters
  • Table 20.6 Continuous Drug Manufacturers: Distribution by Location of Continuous Manufacturing Facilities
  • Table 20.7 Continuous Drug Manufacturers: Distribution by Type of Drug Molecule
  • Table 20.8 Continuous Drug Manufacturers: Distribution by Type of Continuous Manufacturing Related Service
  • Table 20.9 Continuous Drug Manufacturers: Distribution by Type of Dosage Form
  • Table 20.10 AbbVie: Annual Revenues, 2014-2021 (USD Billion)
  • Table 20.11 Cambrex: Annual Revenues, 2014-9M 2019 (USD Million)
  • Table 20.12 Thermo Fisher Scientific Patheon: Annual Revenues, 2014 - H1 2021 (USD Million)
  • Table 20.13 Ajinomoto Bio-Pharma Services: Annual Revenues, FY 2014 - Q1 2021 Revenue (JPY Billion)
  • Table 20.14 Boehringer Ingelheim: Annual Revenues, 2014 - 2021, (EUR Billion)
  • Table 20.15 Lonza: Annual Revenues, 2014 - H1 2021 (CHF Billion)
  • Table 20.16 GEA Group: Annual Revenues, FY 2014 - Q1 2021 (EURP Million)
  • Table 20.17 Kaneka: Annual Revenues, FY 2014 - Q1 2021, (JPY Billion)
  • Table 20.18 WuXi Apptec: Annual Revenues, 2015 - H1 2021 (RMB Million)
  • Table 20.19 ACG Group: Annual Revenues, FY 2014 - Q1 2021 (YEN Million)
  • Table 20.20 Aurobindo Pharma: Annual Revenues, FY 2014 - FY 2021
  • Table 20.21 Partnerships and Collaborations: Cumulative Year-wise Trend, 2013-2021
  • Table 20.22 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 20.23 Partnerships and Collaborations: Year-wise Trend by Type of Partnership 2013-2021
  • Table 20.24 Partnerships and Collaborations: Distribution by Type of Partnership, 2013 - 2015 and 2016-2021
  • Table 20.25 Partnerships and Collaborations: Distribution by Scale of Operation
  • Table 20.26 Partnerships and Collaborations: Distribution by Type of Drug Molecule
  • Table 20.27 Partnerships and Collaborations: Distribution by Type of Continuous Manufacturing Related Service
  • Table 20.28 Partnerships and Collaborations: Distribution by Type of Dosage Form
  • Table 20.29 Most Active Players: Distribution by Number of Partnerships
  • Table 20.30 Partnerships and Collaborations: Regional Distribution
  • Table 20.31 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Table 20.32 Recent Expansions: Cumulative Year-wise Trend, 2013- January 2021
  • Table 20.33 Recent Expansions: Distribution by Type of Expansion
  • Table 20.34 Recent Expansions: Distribution by Type of Drug Molecule
  • Table 20.35 Recent Expansions: Distribution by Type of Continuous Manufacturing Related Service
  • Table 20.36 Recent Expansions: Distribution by Type of Dosage Form
  • Table 20.37 Most Active Players: Distribution by Number of Expansions
  • Table 20.38 Recent Expansions: Intercontinental and Intracontinental Distribution
  • Table 20.39 Recent Expansions: Regional Distribution
  • Table 20.40 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Company Size (in Metric Tonnes / Year)
  • Table 20.41 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Purpose of Manufacturing (in Metric Tonnes / Year)
  • Table 20.42 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Scale of Operation (in Metric Tonnes / Year)
  • Table 20.43 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Location of Headquarters (in Metric Tonnes / Year)
  • Table 20.44 Global, Continuous Manufacturing Capacity for Small Molecule APIs: Distribution by Location of Continuous Manufacturing Facilities (in Metric Tonnes / Year)
  • Table 20.45 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Company Size (in Kgs / Year)
  • Table 20.46 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Purpose of Manufacturing (in Kgs / Year)
  • Table 20.47 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Scale of Operation (in Kgs / Year)
  • Table 20.48 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Location of Headquarters (in Kgs / Year)
  • Table 20.49 Global, Continuous Manufacturing Capacity for Small Molecule End Products: Distribution by Location of Continuous Manufacturing Facilities (in Kgs / Year)
  • Table 20.50 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Company Size (in Kgs / Year)
  • Table 20.51 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Purpose of Manufacturing (in Kgs / Year)
  • Table 20.52 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Scale of Operation (in Kgs / Year)
  • Table 20.53 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Location of Headquarters (in Kgs / Year)
  • Table 20.54 Global, Continuous Manufacturing Capacity for Biologics: Distribution by Location of Continuous Manufacturing Facilities (in Kgs / Year)
  • Table 20.55 Academic Grant Analysis: Cumulative Year-wise Trend, 2016-2021
  • Table 20.56 Academic Grant Analysis: Distribution by Activity Codes
  • Table 20.57 Academic Grant Analysis: Year-wise Distribution on Leading Activity Codes
  • Table 20.58 Academic Grant Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
  • Table 20.59 Academic Grant Analysis: Distribution by Support Period
  • Table 20.60 Popular Recipient Organizations: Distribution by Number of Grants
  • Table 20.61 Popular Recipient Organizations: Distribution by Amount Awarded (USD Million)
  • Table 20.62 Academic Grant Analysis: Distribution by Type of Recipient Organization
  • Table 20.63 Academic Grant Analysis: Distribution by Support Year and Funding Institute Centre
  • Table 20.64 Academic Grant Analysis: Distribution by Funding Mechanism
  • Table 20.65 Prominent Program Officers: Distribution by Number of Grants
  • Table 20.66 Patent Portfolio: Distribution by Type of Patent
  • Table 20.67 Patent Portfolio: Cumulative Year-wise Trend, till 2021
  • Table 20.68 Patent Portfolio: Cumulative Year-wise Trend, till 2021 (Pharmaceutical and Biopharmaceutical Industry)
  • Table 20.69 Patent Portfolio: Distribution by Geography
  • Table 20.70 Patent Portfolio: Distribution of CPC Symbols by Publication Year (Before 2014-2021)
  • Table 20.71 Patent Portfolio: Distribution by Type of Applicant
  • Table 20.72 Leading Industry Players: Distribution by Number of Patents
  • Table 20.73 Leading Non-Industry Players: Distribution by Number of Patents
  • Table 20.74 Patent Portfolio: Distribution of Patents by Age, 2000-2021
  • Table 20.75 Patent Portfolio: Distribution of Patents by Geography, Before 2014-2021
  • Table 20.76 Continuous Manufacturing, 2022-2035: Year-Wise Adoption Curve by Type of Molecule and Manufacturing Service (%)
  • Table 20.77 Overall, Continuous Manufacturing Market, 2022-2035 (USD Million)
  • Table 20.78 Continuous Manufacturing Market: Distribution by Purpose of Manufacturing, 2022-2035 (USD Million)
  • Table 20.79 Continuous Manufacturing Market: Distribution by Scale of Operation, 2022-2035 (USD Million)
  • Table 20.80 Continuous Manufacturing Market: Distribution by Type of Drug Molecule, 2022-2035 (USD Million)
  • Table 20.81 Continuous Manufacturing Market (Small Molecules and Biologics): Distribution by Type of Continuous Manufacturing Related Service, 2022-2035 (USD Million)
  • Table 20.82 Continuous Manufacturing Market (Small Molecules and Biologics): Distribution by Type of Dosage Form, 2022-2035 (USD Million)
  • Table 20.83 Continuous Manufacturing Market (Small Molecules and Biologics): Distribution by Key Geographical Regions, 2022-2035 (USD Million)
  • Table 20.84 Continuous Manufacturing Market for Small Molecule: Distribution by Purpose of Manufacturing, 2022-2035 (USD Million)
  • Table 20.85 Continuous Manufacturing Market for Small Molecule: Distribution by Scale of Operation, 2022-2035 (USD Million)
  • Table 20.86 Continuous Manufacturing Market for Small Molecule: Distribution by Type of Continuous Manufacturing Related Services, 2022-2035 (USD Million)
  • Table 20.87 Continuous Manufacturing Market for Small Molecule: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
  • Table 20.88 Continuous Manufacturing Market for Biologic: Distribution by Purpose of Manufacturing, 2022-2035 (USD Million)
  • Table 20.89 Continuous Manufacturing Market for Biologic: Distribution by Scale of Operation, 2022-2035 (USD Million)
  • Table 20.90 Continuous Manufacturing Market for Biologic: Distribution by Type of Continuous Manufacturing Related Service, 2022-2035 (USD Million)
  • Table 20.91 Continuous Manufacturing Market for Biologic: Distribution by Key Geographical Regions, 2022-2035 (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  • 1. AbbVie
  • 2. AC Immune
  • 3. ACG
  • 4. Ajinomoto OmniChem
  • 5. Almac
  • 6. Amar Chemistry
  • 7. Amgen
  • 8. AMPAC Fine chemicals
  • 9. AMRI
  • 10. Angelini Pharma
  • 11. Arcinova
  • 12. AstraZeneca
  • 13. Asymchem
  • 14. Aurobindo Pharma
  • 15. BASF Pharma
  • 16. Bayer
  • 17. Bellen Chemistry
  • 18. Biosana Pharma
  • 19. BioXcellence (Contract Manufacturing unit of Boehringer Ingelheim)
  • 20. Boehringer Ingelheim
  • 21. Bristol Myers Squibb
  • 22. Cambrex
  • 23. Cell Culture Company
  • 24. Cerbios-Pharma
  • 25. Cipla
  • 26. Colorcon
  • 27. Consort Medical
  • 28. Continuus Pharmaceuticals
  • 29. Corden Pharma
  • 30. Dalton Pharma Services
  • 31. Dottikon Exclusive Synthesis
  • 32. DSM Pharmaceutical
  • 33. Eburon Organics
  • 34. Eli Lilly
  • 35. Enzene Biosciences
  • 36. Esco Aster
  • 37. Evonik
  • 38. Farmhispania
  • 39. FUJIFILM Diosynth Biotechnologies
  • 40. GEA
  • 41. Glatt Group
  • 42. Goodwin Biotechnology
  • 43. Grace
  • 44. GSK
  • 45. Hanmi Pharmaceuticals
  • 46. Hovione
  • 47. InnoSyn
  • 48. Johnson & Johnson
  • 49. Johnson Matthey
  • 50. Kaneka
  • 51. Lonza
  • 52. Medichem
  • 53. Merck
  • 54. NJ Bio
  • 55. Novartis
  • 56. Onyx Scientific
  • 57. Patheon (Thermo fisher scientific)
  • 58. Pfizer
  • 59. PharmaBlock Sciences
  • 60. Phlow
  • 61. Procos
  • 62. Promega
  • 63. Sanofi
  • 64. Servier
  • 65. Siegfried
  • 66. SK Pharmteco
  • 67. STA Pharmaceuticals (a subsidiary of WuXi AppTec)
  • 68. Sterling Pharma
  • 69. Syntegon Technology
  • 70. Vertex Pharmaceuticals
  • 71. WuXi Biologics
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!